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Abstract: The recent rapid growth in dermal filler use, in conjunction with inadequate 
product and injector control, has heralded a concerning increase in filler complications. The 
10-point plan has been developed to minimize complications through careful preconsideration 
of causative factors, categorized as patient, product, and procedure related. Patient-related 
factors include history, which involves a preprocedural consultation with careful elucida-
tion of skin conditions, systemic disease, medications, and previous cosmetic procedures. 
Other exclusion criteria include autoimmune diseases and multiple allergies. The temporal 
proximity of dental or routine medical procedures is discouraged. Insightful patient assess-
ment, with the consideration of ethnicity, gender, and generational needs, is of paramount 
importance. Specified informed consent is vital due to the concerning increase in vascular 
complications, which carry the risk for skin compromise and loss of vision. Informed consent 
should be signed for both adverse events and their treatment. Product-related factors include 
reversibility, which is a powerful advantage when using hyaluronic acid (HA) products. 
Complications from nonreversible or minimally degradable products, especially when layered 
over vital structures, are more difficult to control. Product characteristics such as HA con-
centration and proprietary cross-linking should be understood in the context of ideal depth, 
placement, and expected duration. Product layering over late or minimally degradable fillers 
is discouraged, while layering of HA of over the same brand, or even across brands, seems 
to be feasible. Procedural factors such as photographic documentation, procedural planning, 
aseptic  technique, and anatomical and technical knowledge are of pivotal importance. A 
final section is dedicated to algorithms and protocols for the management and treatment of 
complications such as hypersensitivity, vascular events, infection, and late-onset nodules. 
The 10-point plan is a systematic, effective strategy aimed at reducing the risk of dermal 
filler complications.
Keywords: assessment, complications, dermal fillers, prevention, treatment
Introduction
The use of dermal fillers has experienced tremendous growth over the past years, 
heralding an increase in more serious adverse events. The field of esthetic fillers is 
currently enduring an onslaught of factors compromising not only patient safety but 
also the reputation of the field. Although it is said that the courage of a soldier is 
heightened by his knowledge of his profession (Publius Flavius Vegetius Renatus), 
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in everyday filler practice, it is often the lack of knowledge 
that emboldens the esthetic physician.
In their review of the regulations of cosmetic interven-
tions, the UK Department of Health cautioned that the use of 
injectable fillers is a crisis waiting to happen.1 This warning 
was prompted by several factors, including inadequate regula-
tion of esthetic physicians, suboptimal control of filler quality, 
and the recent rapid growth in the filler market for purely 
financial gain. These factors warrant proactive intervention 
not only in the interest of patient safety but also in the inter-
est of maintaining the credibility and viability of the field.
Filler complications are traditionally divided into four 
categories: allergic, infective, late-onset nodules/inflamma-
tion, and intravascular events.2,3 The incidence of complica-
tions, notably late-onset nodules and intravascular events 
(eg, skin necrosis and blindness), is increasing.4,5 More than 
100 cases of blindness are documented in the literature, with 
most cases reported in recent years.6 These complications 
can be reduced or even prevented by a vigilant, systematic 
approach. This entails careful patient selection, wise product 
choice, aseptic technique, and insightful knowledge  of  facial 
anatomy coupled with constant awareness of the early signs 
of vascular compromise.7
The 10-point plan (10PP) suggested here is a systematic, 
effective strategy aimed at reducing the risk of dermal filler 
complications. It is achieved through conscious awareness 
and careful preconsideration of the possible confounding 
factors specific to each procedure (Table 1). The 10PP is 
also presented in a table form as a quick-reference checklist 
for both entry-level and experienced esthetic physicians. 
Table 1 A 10-point plan for avoiding filler complications
I. Patient II. Product III. Procedure IV. Algorithms
1. History
• Skin conditions
• Systemic disease
• Medication
• Procedures
Selection
• Skin + systemic
• Pretreatment
• Dental, vaccinations
• Routine procedures
• Dysmorphophobia
4. Reversibility
• Hyaluronidase
• Dilution + dosage 
7. Photographs
• Pre and post
• Black background
• No makeup
• Rest and animation
• Angles and lighting
• SLR camera
Allergy/hypersensitivity
• Early: vitals, adrenalin, IV
• Late: cold compress
• H1 + H2 antagonists
• Oral corticosteroids
• Propanol, ibuprofen
5. Product characteristics 
determine placement
• HA concentration
• Cross-linking 
8. Procedural planning and aseptic technique
• Technical flow
• Everything at hand
• Skin: chlorhexidine/alcohol
• Chlorhexidine mouthwash
• Gloves + hand washing
Vascular events
• HDPH
If visual disturbance occurs:
a) stop injecting
b) Consult an ophthalmologist
c) 90-minute timeframe
Infection
• Oral antibiotics
• IV antibiotics
• Hyaluronidase
• Surgical drainage
• Laser
2. Assessment
• Beauty, aging, gender, 
ethnicity
• Wants vs needs
6. Product layering
• HA over minimally 
biodegradable fillers
9. Injection anatomy
• Safety by depth
• Danger areas
Late-onset nodules
• Antibiotics
• Hyaluronidase
• Immunosuppressives
• Tacrolimus
• Pimecrolimus
• Colchicine
3. Consent
• Informed consent
• Procedure + complications
• Financial consent
10. Technical knowledge
• Depth, placement
• Speed
• Needle vs cannula
• Aspiration vs movement
Abbreviations: HA, hyaluronic acid; IV, intravenous; SLR, single-lens reflex.
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The 10 points are further divided into the following three 
categories:
•	 Patient-related factors.
•	 Product-related factors.
•	 Procedure-related factors.
Algorithms for the management of early, intravascular, 
and late-onset events are included.
Patient-related factors
History and selection
The patient is not a blank canvas. Whilst they may have 
requested a procedure, it is the esthetic physician who should 
ultimately “select” the patient. An understanding of the 
treatment motivation is thus vital in minimizing inappropri-
ate patient selection. Obtaining a thorough history of skin 
conditions, allergies, systemic disease, current medication, 
and previous procedures is mandatory.
Patients should be carefully selected by excluding both 
cutaneous and systemic contra-indications. Skin barrier dis-
ruption due to inflammatory or infective conditions allows 
the penetration of infective agents.8 Rosacea is an inflam-
matory condition presenting with decreased barrier function 
and proinflammatory antimicrobial peptides functioning as 
vasoactive mediators.9 In acne, Propionibacterium acnes 
induces a cytokine-mediated inflammasome in which Toll-like 
receptor-2 (TLR-2) has been proven to play a role.10 There are 
increased numbers of resistant P. acnes at the edges of topi-
cally treated acne areas, which may play a role in the formation 
of biofilms. It is important to realize that the “safe distance” 
for filler placement relative to an area of acne is unknown.7 
Pretreatment of inflammatory conditions such as acne, 
rosacea, and dermatitis is important as is allowing adequate 
time for the restoration of barrier function.9 This may require 
3–4 weeks after apparent clearance. It is advisable that patients 
with remote infections involving, for example, the urinary 
tract, sinuses, intestinal tract, and oral cavity are deferred for 
treatment as it has been postulated that hematogenous spread 
of normally non-virulent bacteria may lead to binding to the 
TLR’s with possible triggering of an immune response and 
formation of late-onset nodules.10 It is prudent to note that late-
onset nodules may be preceded by viral or flu-like illness.11 
Prophylactic antivirals to prevent virus reactivation are best 
considered if there is a history of herpes simplex infection 
in the intended injection area.12 Filler treatments are contra-
indicated in active autoimmune diseases such as systemic 
lupus erythematosus, rheumatoid arthritis, mixed connective 
tissue disease, and Hashimoto’s thyroiditis.7,13 It is preferable 
to avoid injecting patients with multiple, severe allergies and 
a history of anaphylaxis since drug allergies might preclude 
optimal management of complications.13
Knowledge of previous surgical and nonsurgical cos-
metic procedures is vital as these could lead to fixation 
and scarring of underlying vasculature, thus facilitating 
intravascular placement by both cannulae and needles. 
Determining the types and location of previously injected 
products may help to prevent compatibility issues with mini-
mally degradable fillers and the intendant risk of late-onset 
nodules.14 Dental procedures and visits to the oral hygienist 
are best avoided during the 2–4-week period before and 
after filler treatment to reduce the risk of hematogenous 
bacterial seeding and potential development of biofilm.15 
Tooth bleaching/whitening frequently implies concomitant 
dental descaling and should also be discouraged during this 
period. It is advisable to structure the treatment plan over 
time, with due consideration to pending medical procedures, 
dental visits, and immunizations, thus limiting inflammatory 
reactions or hypersensitivities due to a heightened immune 
system.7
Unrealistic expectations or signs of body dysmorphic 
disorder are deemed a firm contraindication to cosmetic 
treatment.1
Patients should be given a prefiller checklist serving as 
an exclusion questionnaire and emphasizing the importance 
of having no infective or inflammatory conditions (cutaneous 
or systemic) at the time of treatment. The undesirability of 
dental and routine medical procedures in the period adjacent 
to filler treatment should be noted, and facial procedures 
inducing inflammation or disruption of the skin barrier 
should likewise be planned away from the time of treat-
ment. The checklist should also include a list of common 
blood thinners (medications and foodstuffs) to preferably be 
avoided in the week before treatment (aspirin, nonsteroidal 
anti-inflammatories, salmon oil, vitamin E, gingko biloba, 
red wine, dark chocolate, grapefruit, etc).16 In the author’s 
clinic, it is a standard practice to contact patients 1 week 
before planned treatments to ensure that they are in pos-
session of the prefiller checklist, understand the selection 
criteria, have no precluding factors, and are in possession 
of scripted antivirals where applicable. Investing adequate 
time in the initial consultation is pivotal in optimizing both 
the timing and outcome of the treatment process.
Assessment
Rapid globalization and an increase in social media use 
across generations have fundamentally changed patients’ 
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perceptions of beauty.17 Esthetic inclinations vary and 
the injection specialist should communicate effectively 
to establish underlying motivations, differentiate between 
the patients’ wants and needs, and temper expectations 
within realistic goals.18 The influence of Fitzpatrick skin 
type should be considered for potential post-inflammatory 
hyperpigmentation.19
Consent
Obtaining signed informed consent is crucial in creat-
ing awareness and acceptance of the potential risk of 
filler-induced complications.20 Supplying written pre- and 
post-instructions during the initial consultation can help to 
establish realistic expectations and minimize legal repercus-
sions.21 Moreover, it might be wise to obtain informed consent 
for the management of inadvertent complications, should 
they arise, to expedite efficient management. It is advisable 
to outline the more common adverse events (legally consid-
ered >1% occurrence) as well as those that are particularly 
impactful such as skin necrosis and impairment in vision, 
in the consent form.
Beyond an unnatural look, the three main concerns 
patient face are pain, complications, and procedural costs.22 
It is essential to discuss treatment costs, obtain financial 
consent, and plan over the long term to obviate financial 
stress. Addressing these issues upfront is instrumental in 
establishing the trust that underpins true patient satisfaction.
Product-related factors
reversibility
The reversibility of hyaluronic acid (HA) fillers is a pow-
erful advantage as most complications induced by these 
fillers can be addressed.23 The management of problems 
with irreversible fillers is far more challenging as no spe-
cific dissolving compounds currently exist. These products 
should ideally be restricted to clinicians with experience 
in their use.14
HA fillers can be liquefied by the use of hyaluronidase, 
requiring that injection specialists familiarize themselves 
with the reconstitution and dosage necessary for the treat-
ment of both intravascular complications and cosmetically 
unsatisfactory results.24–26
Product characteristics
The hygroscopic nature of HA is an important determinant 
of product-related swelling as higher HA concentrations, 
associated free HA content, and limited cross-linking result 
in an increased tissue swelling.27 It is important that the 
esthetic physician differentiates between product-related 
swelling and tissue trauma. The HA concentration and the 
extent of cross-linking determine the product’s characteristics 
(viscosity, elasticity, resistance to degradation, G′ [G prime/
elastic modulus], G″ [G double prime/viscous modulus], 
and Tan Delta) and ultimately its clinical efficacy at different 
tissue depths.2,14
Every company obtains their raw HA product as disaccha-
ride chains from the same source after which a solvent is added, 
resulting in a HA liquid with minimal in situ longevity. Cross-
linker (typically 1,4-butanediol diglycidyl ether [BDDE]) is 
therefore added, converting the liquid into a semisolid gel that 
is too firm for syringe injection. Each company has a propri-
etary modification process, which allows a portfolio of HA 
filler consistencies with varied characteristics such as viscosity, 
gel hardness, lifting ability, and tissue integration.28 Therefore, 
cross-linking characteristics are pivotal in determining the 
optimal depth of placement and longevity of the product.
Product layering
A thorough history of previous product use is mandatory. Cer-
tain late or minimally biodegradable fillers may be provoked 
into reactivity by needle trauma alone, or when a second filler 
such as HA is layered over them, thus inducing long-lasting 
complications such as foreign body granulomas.7 Due to the 
inherent longevity associated with minimally biodegradable 
fillers, there is a portended increased incidence in more 
delayed-onset adverse events.27,29 Although HAs remain the 
most compatible fillers, it is important to proceed with cau-
tion when considering cross-brand layering.
Procedure-related factors
Photographs
Photographic records are essential not only for medico-legal 
purposes but also for critical appraisal of planning and results. 
They can serve as a major driver for progression to treatment 
and as an invaluable learning curve for the esthetic physician.3 
To ensure good quality pre- and posttreatment photographs, 
remove all makeup and jewelry, use a hairband and prefer-
ably a black background. Multiple images at rest and during 
animation are recommended, including but not limited to 
anterior, oblique, and lateral views with the head in a neutral, 
neck-extended, and neck-flexed position.30 Proper lighting, 
consistent angles, and fixed distance from the camera are 
mandatory. It is advisable to use a single-lens reflex (SLR) 
camera and tripod rather than mobile cameras as the latter 
are frequently equipped with wide-angle lenses that may lead 
to photographic distortion.
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Procedural planning and aseptic 
technique
Procedural planning is essential in preventing breaching of 
the clean workspace. Ensuring that everything is at hand 
before initiating the treatment helps to reduce breaks in the 
aseptic field and the concomitant risk of injection-related 
infections.31 As with all esthetic procedures, a precon-
ceived plan aids in a clear procedural flow that minimizes 
complications.
Stringent aseptic technique is mandatory.32 The patient’s 
skin should be cleaned, degreased, and disinfected. There 
are no universally recommended topical antiseptics, but 
chlorhexidine, chloroxylenol, iodophors, alcohol, and iodine 
may be appropriate. Makeup should be removed, and the 
skin cleansed carefully with 2% chlorhexidine gluconate in 
70% alcohol, avoiding ocular exposure to the disinfectant. 
Rinsing the mouth with an antiseptic mouthwash contain-
ing chlorhexidine (0,2%) or povidone-iodine sterilizes the 
oral cavity for up to 8 hours and has been suggested as a 
preventative practice when treating the perioral area or those 
patients with a lip-licking habit.15 The esthetic physician 
should remove all jewelry, wash their hands with antiseptic 
cleanser, and use gloves for all cases of injection therapy.33 
The procedure is not deemed to be sterile as the syringe 
itself is not completely sterile. Therefore, once the esthetic 
physician holds the syringe, sterility is lost and aseptic 
technique is of paramount importance. Transferring the 
surgical principles of sterile technique by not touching any 
component of the needle or cannula that penetrates the skin 
may further reduce the prevalence of infective complica-
tions. Constant vigilance against possible contamination is 
of utmost importance.34 Cleansing over a sufficiently broad 
area is imperative as there is a higher infective risk upon 
inadvertent resting of the cannula on the adjacent skin. 
Frequent changing of needles and cannulae is advised when 
utilizing multiple entry points.35
The use of disposable sterile dressing trays with contain-
ers for prep solution, gauze, and disposable sterile drapes 
provides a convenient and inexpensive way to establish a 
safe, clean work area in an office setting.36
Applied facial anatomy
Knowledge of applied facial anatomy is of paramount 
importance and serves as the foundation for avoiding disas-
trous complications.37,45 Multiple documented variations 
and classifications of the vascular arcades in the face render 
it impossible for the injection specialist to determine the 
patient’s anatomy. There is no 100% guarantee of avoiding 
vascular injury once the needle or cannula has penetrated 
beneath the skin. The location of the tip of the needle or 
cannula determines the location of the deposition of product 
and, thus, its embolic potential. Nonetheless, potential dan-
ger areas can be identified by clear anatomical understand-
ing of the depth of neurovascular structures across specific 
facial zones.27 Esthetic physicians should fully understand 
the appropriate depth and plane of injection (safety by 
depth) at different sites of treatment.6,38 Facial injection 
anatomy training is specific for nonsurgical syringe therapy 
and is highly advisable for optimal results and avoidance 
of complications.38 However, even expert esthetic physi-
cians have a substantial history of intravascular injection 
in their careers with 61% of trainers inducing at least one 
such episode.39
Technical knowledge
Knowledge of optimal placement and injection depth is 
cardinal to the esthetic success of dermal fillers. Unduly 
superficial placement may lead to adverse effects such as 
surface irregularities and the Tyndall effect.40 The hallmarks 
of sage injection technique include slow injection speed with 
least amount of pressure and small bolus size.41 Although 
controversial, the merits of aspiration before injection 
(especially in high-risk areas), vs constant movement of 
the tip of the needle, should be considered. Incremental 
injections of 0.1–0.2 cc of the product should be used while 
continually monitoring the skin of the surrounding area.42 
Rapid injection speed, aggressive fanning, high-volume filler 
deposits, and large bolus size induce increased bruisability 
and the occurrence of delayed inflammatory reactions.40,43 
The esthetic physician should understand the relative risks 
and advantages of using a needle vs cannula. Small-bore 
needles are recommended by some to slow the injection 
rate, and blunt cannulae are suggested in high-risk regions 
in an attempt to reduce vessel injury.2 Surgery, scarring, or 
multiple previous procedures may increase the risk of can-
nulating a vessel.25
Algorithms
Algorithms and protocols
Complication management and recognition are the most 
significant unmet needs with HA fillers.2 From a temporal 
perspective, filler complications may be divided into early-
onset (vascular, inflammatory, injection related, placement, 
and distant spread) and late-onset (inflammatory, nodules, 
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dyspigmentation, and displacement) events. An alternative 
classification would include
•	 Allergic/hypersensitivity,
•	 Vascular events,
•	 Infective,
•	 Late-onset nodules or inflammation.
To ensure the optimal management of untoward events, 
it is prudent to have easily accessible practice protocols 
and algorithms as well as an excellent collegial backup 
system. A direct line to an ophthalmologist experienced 
in treating retinal artery occlusion and administering 
retrobulbar hyaluronidase is highly advisable. Efficient 
structures need to be in place for the treatment of both 
early- and delayed-onset reactions, and regular checks of 
expiry dates on emergency drugs (programmed computer 
prompts) should be instituted.
Post-treatment checklist
•	 Routinely check perfusion in the treated areas as well as 
areas with watershed perfusion (glabella, nasal tip, and 
upper lip) ensuring that makeup is not obscuring skin 
tone. Initial signs of vascular compromise may be subtle.
•	 The patient should be furnished with written posttreat-
ment instructions and contact numbers.
•	 The esthetic physician/clinic should be available tele-
phonically for 48 hours postprocedure.
•	 It is good practice to have a staff member call the patient 
the next day.
Hypersensitivity
Hypersensitivity or allergic reactions can occur when the 
injected filler activates an immune response.3,5,44 With early-
onset hypersensitivity reactions, check vital signs and have 
resuscitation measures such as adrenalin, intravenous (IV) 
access, and fluids in place. Cold compresses may be used 
for delayed onset localized angioedema, with H1-receptor 
antagonist for histamine-induced hypotension and the 
reduction in pruritus.15 H2-receptor antagonists, oral cor-
ticosteroids, or ibuprofen may be considered as additional 
measures (Table 2).7
Vascular events
The first symptoms of intravascular placement are often 
(but not always) pain and skin color change, which may be 
remote from the injection point. Although the first symptom 
of intravascular placement is often described as pain, the com-
mon addition of local anesthetics to filler formulations may 
obviate this sign. Vigilant observation of skin color change, 
which may be remote from the injection point, is mandatory. 
Although usually immediate, the onset has been reported 
to be delayed up to 24 hours. Any suspicion of inappropri-
ate pain, skin blanching, or mottled discoloration warrants 
immediate cessation of injection with the application of 
warm compresses, injection of hyaluronidase, and massage 
of the affected area. The patient should be given two tablets 
(650 mg) of aspirin to chew and swallow.45 High-dose hyal-
uronidase (500–1000 IU) mixed with lidocaine in repeated 
hourly doses for 3 hours forms the backbone of the emergent 
therapy (Table 3).25 It is advisable to use a large bore cannula 
for instillation of the hyaluronidase in the subdermal plane 
to avoid bruising, which would confound the visual feedback 
of improving skin color.
For ophthalmic events, the following is suggested:
• Contact the ophthalmologist of choice directly and 
accompany the patient to his office.
• Respect the absolute 90-minute time frame for saving the 
loss of vision.46
• Have multiple vials of hyaluronidase at hand and be 
knowledgeable regarding reconstitution and dosage.
• Carry own hyaluronidase to the ophthalmologist.
• If possible, annotate the time of the vascular event and 
the visual acuity if lack of light perception (LP) or loss 
of vision occurs
• To facilitate accurate ophthalmological follow-up, imme-
diate recording of vision should be annotated as no light 
perception (NLP), LP, hand motion (HM), and count 
fingers (CF), followed by a Snellen chart if available. An 
afferent pupillary defect should be noted if present.
• Attempt rapid ocular pulsed massage.
• Having the patient hyperventilate in a paper bag may 
promote retinal vessel dilation.
Table 2 Algorithm for early and delayed hypersensitivity 
reactions
Hypersensitivity reactions
Early Delayed
Check vital signs Cold compresses
resuscitation measures:
Adrenalin
Iv access
Fluids
H1-receptor antagonists
H2-receptor antagonists
Leukotriene synthesis inhibitors
Oral corticosteroids
Propranolol
Ibuprofen
Abbreviation: Iv, intravenous.
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It is important to note that complications such as panoph-
thalmoplegia, pulmonary embolism, and cerebral infarction 
have been reported after filler injections.47
Infection
Injecting dermal fillers breaches the skin barrier, thus posing 
a risk of infection.32 The latter can be broadly categorized 
as acute infections, which appear as acute inflammation or 
abscesses at the site of injection, or as delayed-onset chronic 
infections, which generally develop 2 or more weeks after 
initial treatment. The differential diagnosis of cellulitis vs 
pure inflammation is often clinically challenging in the 
absence of fever or abscess formation and may require 
aspiration, culture, and blood tests to confirm etiology. Sys-
temic steroids, although indicated to quell inflammation, are 
contraindicated in cases of infection. Infection can be treated 
with oral antibiotics, which exert immunomodulatory and 
anti-inflammatory effects.27,48,49 For additional treatment, 
hyaluronidase, IV antibiotics, laser, or surgical drainage of 
the abscess may be considered.14
Late-onset nodules
Late-onset nodules (4 weeks to >1 year posttreatment) most 
likely occur due to inflammatory or biofilm-related causes.50 
The etiology of the nodules may be related to prolonged 
mechanical irritation or hematogenous seeding of relatively 
innocuous bacteria from a distant site (eg, dental cleaning). 
Binding of nonvirulent infectious agents around the time 
of procedure may lead to an immune response mediated 
via TLRs. For late-onset nodules, the use of antibiotics, 
hyaluronidase, topical tacrolimus (0.1%) or pimecrolimus 
(1%), and bacteriostatic/immunosuppressive agents such 
as hydroxychloroquine, cyclosporin A, and methotrexate 
depending on the etiology of the nodules is considered 
(Table 4).5,51 Recently, the successful use of colchicine has 
also been proposed (submitted for publication).
Conclusion
This 10PP not only informs safer practice but hopefully also 
deepens consideration of the factors that can safeguard the 
field of esthetic fillers. From the importance of careful patient 
Table 3 DeLorenzi’s HDPH dosage and protocol
High-dose pulse hyaluronidase
Dosage standard dosage 500 IU per area
Lip, nose, and forehead Act as multipliers
two areas 1,000 IU per hour
three areas 1,500 IU per area
Protocol
• Inject at least every 60–90 minutes until skin color has normalized and capillary refill time has normalized
• Massage to increase embolus contact with the hyaluronidase by propelling the HA distally into thinner-walled arterioles
• Aim to complete treatment within 72 hours of onset for complete resolution
• Keep patient in clinic for observation and treatment until the capillary refill has improved (usually three sessions over 3 hours)
• Do not apply nitroglycerin paste until the offending HA has been dissolved (day 2 or 3 of treatment) as dilation of adjacent nonobstructed 
vascular pathways can lead to the propagation of the embolus toward the orbit
Abbreviation: HA, hyaluronic acid; HDPH, high-dose pulse hyaluronidase. 
Table 4 Algorithm for single or multiple late-onset nodules
Single nodule Multiple nodules
Inflammatory Noninflammatory Consider systemic diseases
Fluctuant Nonfluctuant encapsulated hematoma If biofilm or granuloma
Abscess Biofilm or granuloma Wait topical immunosuppressants
Puncture + drain Hyaluronidase + antibiotics Puncture + drain
Antibiotics Intralesional steroids Antibiotics Antibiotics for example:
Hyaluronidase Ciprofloxacin 500–700 mg bd (2–4 weeks)
Clarithromycin 500 mg bd +
Moxifloxacin 400 mg bd (10 days)
Minocycline 100 mg/day (6 months)
Levofloxacin (3 weeks) followed by additional 
clarithromycin (3 weeks)
Hyaluronidase + antibiotics
Colchicinea
Note: aUnpublished data.
Abbreviation: bd, twice daily.
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selection, through informed product choice, to vigilant 
procedural planning, the esthetic physician is empowered 
to perform optimally. The most feared complications are 
vascular compromise and blindness. Again, it is the detailed 
knowledge of facial anatomy combined with a systematic 
approach and the availability of appropriate algorithms that 
allows the esthetic physician to proceed with confidence.
As previously stated, the majority of adverse events are 
avoidable. Through vigilant practice, we may attempt to 
safeguard our patients and mitigate the threat to the field of 
esthetic fillers from within.
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